Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.

ABSTRACT: Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients' molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patient

SUBMITTER: Morfouace M 

PROVIDER: S-EPMC9117328 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature